MIRA Company Profile and Key Details

Short-term trend indicators are bullishly aligned (SMA20 9.44%, SMA50 -3.03%, SMA200 -5.29%). The stock’s 14-day RSI is 56.74 (neutral), while the ATR of 0.07 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -45.71% below its high and over 82.19% above its low. Average 10-day trading volume of 107.94 thousand shares is below the 3-month average of 149.80 thousand, indicating normal recent market interest.

MIRA Pharmaceuticals, Inc. generated EPS of -$1.52 over the past year. Five-year average earnings growth is -224.25%. MIRA Pharmaceuticals, Inc. earnings surprise history is a mixed track record. The quarter that ended March 31, 2026, missed forecasts by 275.0%. The prior quarter beat by 1375.0%. Over the last six quarters, Apple has recorded several small beats. These include -48.28% in March 28, 2025.

MIRA Pharmaceuticals, Inc. has 19.07 million shares outstanding. The public float is 14.67 million shares, elevated short interest at 2.66% of float. This equals 388.88 thousand shares. The short ratio is 0.12 days. Institutional investors hold 7.12% of the float. Insiders own 16.59%.

MIRA Pharmaceuticals, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.27. This means the shares are trading above this model’s fair value.

MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) closed at $1.01 USD, gaining $0.02 (2.53%) from the previous close of $0.99. The stock is currently mid-range between its 52-week high and low $0.90 and $2.45. With a market capitalization of about $42.65 million, MIRA Pharmaceuticals, Inc. is classified as a micro-cap and shows higher-than-market volatility (beta ~1.50). Key stats such as the average daily volume over the past year has been around 153.47 thousand shares, volume is running light vs its 52-week average. Headquartered in Baltimore, MD, MIRA Pharmaceuticals, Inc. operates in the Healthcare sector and the Drug Manufacturers - General industry. Led by CEO Erez Aminov, the company employs approximately 2 people and listed since August 14, 2023. MIRA Pharmaceuticals, Inc. operates as a clinical development stage biopharmaceutical company.

MIRA Pharmaceuticals, Inc. trades at a P/E ratio of -0.74, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 2.29 suggesting the stock is closer to book value. The P/FCF stands at -9.06, also above market averages.

Our AI price prediction model suggests that MIRA Pharmaceuticals, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 1.01%, with price expected at $1.00 by May 25, 2026, within a range of $0.94 to $1.05 3-Month Outlook: Projected fall of -2.02%, reaching $0.97 by August 07, 2026, with a range of $0.91 to $1.02. 1-Year Outlook: Projected gain of 135.35%, with price at $2.33 by May 11, 2027, within a range of $1.23 to $2.52.

MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) shares are flat -3.97% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows MIRA Pharmaceuticals, Inc. trading at a premium to the broader market with a P/E of -0.74. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $17.00, suggesting 1617.17% upside. Our AI forecast model points to short-term strength (1.01% over two weeks), a medium-term fall (-2.02% over three months), and a longer-term gain (135.35% over one year), with expected trading ranges indicating moderate volatility.